CP
ARQT icon

Castleview Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Castleview Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,113
Closed -$75.5K – 567
2024
Q2 		$75.5K Buy
+8,113
New +$73.4K 0.04% 267

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Castleview Partners's ARQT Position: Q3 2024 in Review

Castleview Partners sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 8,113 shares — an estimated $75.5K sold.

Castleview Partners first reported a position in ARQT in Q2 2024 and held it in 1 quarter. The position peaked at $75.5K in Q2 2024. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

  • Castleview Partners reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Castleview Partners sold 8,113 Arcutis Biotherapeutics shares in Q3 2024, an estimated $75.5K.
  • Castleview Partners first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 1 quarter.
  • Castleview Partners's Arcutis Biotherapeutics position peaked at $75.5K in Q2 2024.
  • 188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.